Absence of Alternative Therapies for Psoriatic Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan

Absence of Alternative Therapies for Psoriatic Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Oct. 25, 2012 - Pharmaceutical companies need to introduce safe and effective therapies for patients that do not respond to TNF inhibitors MOUNTAIN VIEW, California, Oct. 25, 2012 /PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unmet need for alternative therapies for TNF inhibitor refractory patients. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) United States Market for Psoriatic Arthritis Pharmacotherapy research finds that psoriatic arthritis pharmacotherapeutics prescribed as add-on therapies to standard background therapy earned revenues of approximately $751.5 million in 2011. Frost & Sullivan estimates this to reach $1.3 billion in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. TNF inhibitors, a well-established drug class, have laid the groundwork for the next-generation of effective disease modifying antirheumatic drugs and biologics with improved safety and efficacy profiles.